看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。7 t6 w% l+ m, {
" F) f. k% w1 Z# P. h6 A- F, n% V c. v6 [2 H, \
Currently available feasibility data for possible combination strategies.
0 s9 F, z+ \. Y& _5 V/ E————————————————————————————————5 B) I i1 H" V5 Z( K$ {
Combination Feasibility according to preliminary data
% x) K* l, q3 o( [% n——————————————————————————————————* M5 S/ ?. E ?. [' B: c2 D
Bevacizumab + sorafenib Yes, reduced dose
4 z+ _: C5 c2 ?3 d3 P: uBevacizumab + sunitinib† No : c, J6 J7 F; M' E' D+ S
Bevacizumab + temsirolimus Yes
5 v2 o+ D% r. ^7 d$ |Bevacizumab + everolimus Yes
Y8 Y% o! Z: i4 ~9 t; _/ S0 \9 jSorafenib + sunitinib ? 7 V% l/ J" Q' @ d, t
Sorafenib + temsirolimus Yes, reduced dose
; m9 P/ W: D6 M' D& DSorafenib + everolimus Yes, reduced dose
$ O0 a) `6 ^6 N# i4 S# c/ jSunitinib + temsirolimus† No
0 w6 J* r! t0 w4 B# q: NSunitinib + everolimus ?
7 K6 X* ]" e: e1 Z8 BTemsirolimus + everolimus ?
5 q5 W# f& V6 q D# I7 B# }2 a5 W, d————————————————————
' Q, }1 P; \/ T5 W: U) U†Led to US FDA warning.# g* L4 Q3 @( \1 u1 I
?: As yet unattempted combination.7 Q& b; ~2 A( V! X# C: k W$ W* _/ l
|